TheraRadar
Data updated: Jun 28, 2026

CEFDINIR · ALKEM LABS LTD

Infectious Disease Approved 1997-12-04

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.

Source: FDA Label
NDA
Small Molecule
9
Indications
--
Phase 3 Trials
28
Years on Market

Details

Status
Prescription
First Approved
1997-12-04
Routes
ORAL
Dosage Forms
CAPSULE, FOR SUSPENSION

CEFDINIR Approval History

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
84 FDA actions from 2006 to 2023
Jun 2023 SUPPL
Label · Labeling
Feb 2021 ORIGINAL
Update
Aug 2020 SUPPL
Label · Labeling

What CEFDINIR Treats

7 indications

CEFDINIR is approved for 7 conditions since its original approval in 2006. These indications span multiple therapeutic areas including oncology, immunology, and more.

Source: FDA Label

CEFDINIR Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to CEFDINIR

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AZITHROMYCIN
AZITHROMYCIN
4 shared
NOVEL LABS INC
Shared indications:
Uncomplicated Skin and Skin Structure InfectionsCommunity-Acquired PneumoniaPharyngitis +1 more
CEFPODOXIME PROXETIL
CEFPODOXIME PROXETIL
4 shared
Aurobindo Pharma
Shared indications:
PharyngitisTonsillitisCommunity-Acquired Pneumonia +1 more
CLARITHROMYCIN
CLARITHROMYCIN
4 shared
JUBILANT CADISTA
Shared indications:
Acute Maxillary SinusitisCommunity-Acquired PneumoniaPharyngitis +1 more
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT02891915 results posted 14-0079 HHSN272201300023I Ph 4 completed Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CEFDINIR FDA Label Details

Indications & Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension is indicated for the treatment of patients wit...

Looking for the branded version?

OMNICEF

Full clinical data, patents, trials, and competitive landscape for cefdinir.

See OMNICEF

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.